Financial Survey: Ovid Therapeutics (NASDAQ:OVID) vs. Liquidia (NASDAQ:LQDA)

Ovid Therapeutics (NASDAQ:OVID) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Profitability

This table compares Ovid Therapeutics and Liquidia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-23.64%	-20.52%
Liquidia	30.74%	149.65%	36.30%

Valuation & Earnings

This table compares Ovid Therapeutics and Liquidia”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25 million	72.19	-$17.41 million	($0.31)	-8.65
Liquidia	$158.32 million	38.70	-$68.92 million	$1.37	49.96

Ovid Therapeutics has higher earnings, but lower revenue than Liquidia. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Ovid Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Ovid Therapeutics and Liquidia, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1	0	8	1	2.90
Liquidia	2	3	5	1	2.45

Ovid Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 123.88%. Liquidia has a consensus price target of $98.08, indicating a potential upside of 43.29%. Given Ovid Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Ovid Therapeutics is more favorable than Liquidia.

Summary

Liquidia beats Ovid Therapeutics on 8 of the 14 factors compared between the two stocks.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.